Phase IINeuropeptide
Compound 61897
Formula Pending
Molecular Mass
N/A
CAS Registry
AUTO-061897
Risk Class
HIGH
Last Audit
Sep 25, 2108
Research Abstract
Neuropeptide candidate engineered for endocrine support initiatives with automated dossier coverage.
Compound 61897 is a neuropeptide asset inside neuropeptide innovation track initiatives, optimized for endocrine support and performance longevity.
The dossier currently sits in phase ii with a high risk rating, meaning it is restricted to black-box teams with hardened compliance.
Supply records cite CAS AUTO-061897 with updates logged 2108-09-25.
Acquisition Protocol
Authorized research personnel may request deployment of this compound for laboratory analysis.
Primary Vectors
Endocrine supportPerformance longevity
Nomenclature
CX-61897Neuropeptide Program 61897
Reference Material
- [1] Anubis Compound Registry • CAS AUTO-061897
- [2] Operations Pulse • Neuropeptide innovation track
- [3] Risk Governance Ledger • HIGH clearance for COMPOUND-61897